NanoSiliCal Devices Srl
STAND A44

NanoSiliCal Devices Srl

NanoSiliCal Devices: the Philosophy of smartly developing drugs

Start-up of Regione Calabria

Regione Calabria

Start-up

www.nanosilicaldevices.com
info@nanosilicaldevices.com

P. Bucci,  44A
Rende  (CS) — 87036 — Italia
Phone 00390984496642; 00393280462062

Description

NanoSiliCal Devices (NSD), an innovative small company, a spinoff of the University of Calabria, develops intelligent chemotherapy drugs to increase the efficacy and reduce the toxicity of traditional therapies. The first patented prototype (TRL-7) is ready for pre-clinical and clinical trials. The company also develops nanotechnological solutions for cancer immunotherapy.



The nanodevices developed are aimed at medium/large pharmaceutical companies with which to establish a partnership for the joint development of the drugs of interest or send the systems already developed by NSD to the regulator. This latter activity may also be of interest to Venture Capitalists.

Our products

FOL-MSN-BTZ a nanosystem capable of delivering bortezomib only to tumor tissues

FOL-MSN-BTZ a nanosystem capable of delivering bortezomib only to tumor tissues

NanoSiliCal Devices proposes to investors and companies, with the latter in partnership for joint development, the fully engineered patented nanosystem (EP3288955B1) called FOL-MSN-BTZ which releases bortezomib, a drug used in multiple myeloma, in response to an acidity stimulus within tumor cells. FOL-MSN-BTZ reaches the internal compartments of tumor cells via a receptor-specific entry mechanism promoted by folic acid. The nanosystem (TRL7) is injected intravenously and is patented and can replace bortezomib with better efficacy and less toxicity. Bortezomib is currently a generic drug marketed by at least 16 companies worldwide. The system is produced starting from biocompatible and biodegradable mesoporous silica nanoparticles and the particles that do not reach the tumor are excreted by the glomerular route, thus eliminating even the unused drug in an inactive form.
CD38-MSN-BTZ nanosystem capable of delivering bortezomib only to tumor tissues

CD38-MSN-BTZ nanosystem capable of delivering bortezomib only to tumor tissues

NanoSiliCal Devices offers to investors and companies, with the latter in partnership for joint development, the fully engineered patented nanosystem (EP3288955B1) called CD38-MSN-BTZ which releases bortezomib, a drug used in multiple myeloma, in response to an acidity stimulus within tumor cells. CD38-MSN-BTZ enters tumor cells through a receptor-specific entry mechanism promoted by a peptide specific for the CD38 receptor on myeloma cells. The nanosystem (TRL5) is injected intravenously and can replace bortezomib with better efficacy and less toxicity. Bortezomib is currently a generic drug marketed by at least 16 companies worldwide. The system is produced from biocompatible and biodegradable mesoporous silica nanoparticles and the particles that do not reach the tumor are excreted by the glomerular route thus eliminating, in an inactive form, even the unused drug.